Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 2/20 | 0.41 |
| ▸ | CASR | P41180 | 11/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4142867 | 0.85 | CASR (0.54) | P2RX3CASR | |
| SCHEMBL4135003 | 0.77 | P2RX3 (0.46) | P2RX3CASRPARP1TNKS2PARP2 | |
| SCHEMBL4143990 | 0.76 | KDR (0.41) | PARP1PARP2MEN1KMT2APTGDR2 | |
| SCHEMBL4135896 | 0.70 | TP53 (0.43) | P2RX3CASRTP53NR1I2 | |
| SCHEMBL4143940 | 0.70 | CASR (0.54) | CASR | |
| SCHEMBL4140446 | 0.68 | PDE10A (0.44) | P2RX3CASRTP53PTGDR2 | |
| SCHEMBL5189813 | 0.66 | CASR (0.56) | CASR | |
| SCHEMBL4135630 | 0.66 | C5AR1 (0.50) | TP53MEN1KMT2A | |
| SCHEMBL4142349 | 0.66 | TP53 (0.51) | CASRTNKS2TP53KMT2A | |
| SCHEMBL30915382 | 0.66 | C5AR1 (0.42) | P2RX3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137557-A1 | Calcilytic Compounds | CALCR, SOST, CALCB | P2RX3 1604/4885CASR 12/4885PARP1 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.